Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial.
Ballhausen A, Karthaus M, Fruehauf S, Graeven U, Müller L, König AO, von Weikersthal LF, Sommerhäuser G, Jelas I, Alig AHS, Kurreck A, Stahler A, Goekkurt E, Held S, Kasper S, Heinrich K, Heinemann V, Stintzing S, Trarbach T, Modest DP. Ballhausen A, et al. Among authors: jelas i. ESMO Open. 2024 Jul;9(7):103628. doi: 10.1016/j.esmoop.2024.103628. Epub 2024 Jul 13. ESMO Open. 2024. PMID: 38996519 Free PMC article. Clinical Trial.
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
Modest DP, Heinemann V, Schütt P, Angermeier S, Haberkorn M, Waidmann O, Graeven U, Wille K, Kunzmann V, Henze L, Constantin C, de Wit M, Denzlinger C, Ballhausen A, Kurreck A, Jelas I, Alig AHS, Stahler A, Stintzing S, Oettle H. Modest DP, et al. Among authors: jelas i. J Cancer Res Clin Oncol. 2024 Jul 1;150(7):332. doi: 10.1007/s00432-024-05827-x. J Cancer Res Clin Oncol. 2024. PMID: 38951245 Free PMC article. Clinical Trial.
VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.
Kreutzinger V, Pankow A, Boyadzhieva Z, Schneider U, Ziegeler K, Stephan LU, Kübke JC, Schröder S, Oberender C, le Coutre P, Stintzing S, Jelas I. Kreutzinger V, et al. Among authors: jelas i. J Clin Med. 2024 Feb 12;13(4):1049. doi: 10.3390/jcm13041049. J Clin Med. 2024. PMID: 38398362 Free PMC article.
Tumour mutational burden and survival with molecularly matched therapy.
de Bortoli T, Benary M, Horak P, Lamping M, Stintzing S, Tinhofer I, Leyvraz S, Schäfer R, Klauschen F, Keller U, Stenzinger A, Fröhling S, Kurzrock R, Keilholz U, Rieke DT, Jelas I. de Bortoli T, et al. Among authors: jelas i. Eur J Cancer. 2023 Sep;190:112925. doi: 10.1016/j.ejca.2023.05.013. Eur J Cancer. 2023. PMID: 37544709
Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.
Rieke DT, de Bortoli T, Horak P, Lamping M, Benary M, Jelas I, Rüter G, Berger J, Zettwitz M, Kagelmann N, Kind A, Fabian F, Beule D, Glimm H, Brors B, Stenzinger A, Fröhling S, Keilholz U. Rieke DT, et al. Among authors: jelas i. BMC Med. 2022 Oct 24;20(1):367. doi: 10.1186/s12916-022-02560-5. BMC Med. 2022. PMID: 36274133 Free PMC article.
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.
Möhrmann L, Werner M, Oleś M, Mock A, Uhrig S, Jahn A, Kreutzfeldt S, Fröhlich M, Hutter B, Paramasivam N, Richter D, Beck K, Winter U, Pfütze K, Heilig CE, Teleanu V, Lipka DB, Zapatka M, Hanf D, List C, Allgäuer M, Penzel R, Rüter G, Jelas I, Hamacher R, Falkenhorst J, Wagner S, Brandts CH, Boerries M, Illert AL, Metzeler KH, Westphalen CB, Desuki A, Kindler T, Folprecht G, Weichert W, Brors B, Stenzinger A, Schröck E, Hübschmann D, Horak P, Heining C, Fröhling S, Glimm H. Möhrmann L, et al. Among authors: jelas i. Nat Commun. 2022 Aug 2;13(1):4485. doi: 10.1038/s41467-022-31866-4. Nat Commun. 2022. PMID: 35918329 Free PMC article.
Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers.
Fischer LE, Stintzing S, Heinemann V, Keilholz U, Keune D, Vollbrecht C, Burmeister T, Kind A, Weiss L, Horst D, Kirchner T, Klauschen F, Jung A, Westphalen CB, Jelas I. Fischer LE, et al. Among authors: jelas i. Front Oncol. 2022 May 12;12:870411. doi: 10.3389/fonc.2022.870411. eCollection 2022. Front Oncol. 2022. PMID: 35646657 Free PMC article.
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
Kurreck A, Heinemann V, Fischer von Weikersthal L, Decker T, Kaiser F, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Graeven U, Heinrich K, Held S, Stahler A, Alig AHS, Jelas I, von Einem JC, Stintzing S, Giessen-Jung C, Modest DP. Kurreck A, et al. Among authors: jelas i. Front Oncol. 2022 Feb 18;12:751453. doi: 10.3389/fonc.2022.751453. eCollection 2022. Front Oncol. 2022. PMID: 35251955 Free PMC article.
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.
Alig AHS, Heinemann V, Geissler M, Fischer von Weikersthal L, Decker T, Heinrich K, Held S, Weiss L, Fischer LE, Moosmann N, Stahler A, Jelas I, Kurreck A, von Einem JC, Reinacher-Schick AC, Tannapfel A, Giessen-Jung C, Stintzing S, Modest DP. Alig AHS, et al. Among authors: jelas i. Cancers (Basel). 2022 Jan 21;14(3):526. doi: 10.3390/cancers14030526. Cancers (Basel). 2022. PMID: 35158793 Free PMC article.
21 results